How do HMG-CoA reductase inhibitors prevent stroke?

American Journal of Cardiovascular Drugs

Volumn 2, Issue 1, 2002, Pages 7-14

  Bedi, Ashwani ^a   Flaker, Gregory C ^a  

^a University of Missouri   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; ANTIOXIDANT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 13A; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; CHOLESTEROL; CLOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METALLOPROTEINASE; MEVINOLIN; PLACEBO; PLASMIN; PRAVASTATIN; PROTHROMBIN; SIMVASTATIN; STREPTOKINASE; THROMBIN; THROMBOPLASTIN; UNINDEXED DRUG; UROKINASE;

ACUTE HEART INFARCTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; BLOOD VESSEL INJURY; CAROTID ARTERY DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG INHIBITION; DRUG MECHANISM; FIBRINOLYSIS; HEART LEFT VENTRICLE FUNCTION; HUMAN; INCIDENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; REMISSION; RISK FACTOR; VASCULAR ENDOTHELIUM;

EID: 0036243351     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129784-200202010-00002     Document Type: Article

References (82)

1. Heart and stroke facts
2. The brain at risk - Understanding and preventing stroke
3. Cardiogenic brain embolism
4. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450 000 people in 45 prospective cohorts
5. Lowering blood cholesterol to prevent heart disease
6. Review of lipid-lowering clinical trials in relation to observational epidemiological studies
7. Influence of total cholesterol, high density lipoprotein cholesterol and triglycerides on risk of cerebrovascular disease: The Copenhagen City Heart Study
8. Cholesterol reduction and the risk for stroke in men: A meta-analysis of randomized, controlled trials
9. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial
10. Some risk factors related to the annual incidence of cardiovascular disease and death using pooled biennial measurements
11. WHO cooperative trial on primary prevention of ischemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up. Report of the committee of principal investigators
12. Serum cholesterol and mortality in a Japanese-American population: The Honolulu Heart Program
13. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence of coronary heart disease
14. For the Cholesterol and recurrent Events Trial Investigators. The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels
15. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
16. Prevention of coronary disease with pravastatin in men with hypercholesterolemia
17. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
18. Cholesterol lowering with statin drugs, risk of stroke and total mortality: An overview of randomized trials
19. Reduction of stroke events with pravastatin: The prospective pravastatin pooling project
20. Pravastatin therapy and risk of stroke
21. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
22. Reduction in Stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol
23. Carotid artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults
24. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC II)
25. A population based primary prevention trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries
26. Hypolipidemic drugs reduce lipoprotein susceptibility to undergo lipid peroxidation: In vitro and ex vivo studies
27. Simvastatin inhibits the oxidation of low density lipoproteins by activated human monocyte-derived macrophages
28. Stability and instability: Two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995
29. Molecular basis of acute coronary syndromes
30. The unstable atheroma
31. Strategies to achieve coronary arterial plaque stabilization
32. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits
33. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases and cell death in human carotid plaques. Implication for plaque stabilization
34. Newer risk markers and surrogate endpoints in atherosclerosis management
35. Long-term effects of pravastatin on plasma concentration of C-reactive protein
36. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
37. C-reactive protein and outcome after ischemic stroke
38. Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study
39. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly
40. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis
41. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects
42. Inhibition of proinflammatory cytokine production by pravastatin
43. Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia
44. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
45. Systemic nature of endothelial dysfunction in atherosclerosis
46. Nitric oxide and the cerebral circulation
47. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase
48. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decrease platelet activation, and protects from cerebral ischemia in normocholesterolemic mice
49. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)CoA reductase inhibitors mediated by endothelial nitric oxide synthase
50. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation
51. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthesis in mice
52. Simvastatin, an HMG-Coenzyme A reductase inhibitor, improves endothelial function within 1 month
53. Atherosclerotic plaque rupture in symptomatic carotid artery stenosis
54. Effects of lipids and lipoproteins on thrombosis and rheology
55. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation
56. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia
57. Vastatins inhibit tissue factor in cultured human macrophages
58. Effects of lovastatin therapy on plasminogen activator inhibitor-1 antigen levels
59. Effect of atorvastatin on plasminogen activator inhibitor type-1 synthesis in human monocytes/macrophages
60. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme
61. Regulation of the mevalonate pathway
62. Geranylgeranylated proteins
63. Low molecular weight GTP-binding proteins (LMGPs) involved in vesicular transport: Binary switches or biological transducers?
64. Lipid modification of G proteins
65. Tissue factor and haemostasis
66. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
67. Procoagulant activity expression by macrophages from atheromatous vascular plaques
68. Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia
69. The prevalence of ulcerated plaques in the aortic arch in patients with stroke
70. Mobile aortic atheroma and systemic emboli: Efficacy of anticoagulation and influence of plaque morphology on recurrent stroke
71. Protruding atheromas in the thoracic aorta and systemic embolization
72. Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke
73. Predisposing risk factors and natural history of acute neurologic complications of left-sided cardiac catheterization
74. Stroke as a complication of cardiac catheterization: Risk factors and clinical features
75. Predictors of stroke after cardiac surgery
76. Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia
77. Mechanisms of late stroke after myocardial infarct: The Lausanne Stroke Registry
78. Ventricular dysfunction and the risk of stroke after myocardial infarction
79. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
80. Factors predisposing to the development of atrial fibrillation
81. Echocardiographic predictors of stroke in patients with atrial fibrillation: A prospective study of 1066 patients from 3 clinical trials
82. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation study